 Praxis Precision Medicines Incs NASDAQ:PRAX lead asset has demonstrated encouraging data for central nervous system diseases and has a broad pipeline that targets both prevalent and rare disorders, according to BofA Securities. The Praxis Precision Medical Analyst: Tazeen Ahmad initiated coverage of Praxis Precision Medical with a Buy rating and a price target of 28. 